XML 55 R38.htm IDEA: XBRL DOCUMENT
v3.21.2

Acquisitions (Tables) | 12 Months Ended
--- | ---
Jun. 30, 2021
Business Combinations [Abstract] |
Summary Of Company's Acquisition Activity | The following briefly describes the Company’s acquisition activity for the three years ended June 30, 2021.
Year Ended June 30, |  | Company Name |  | Description of the Business |  | Description of the Acquisition
2021 |  | Sun Nuclear |  | Sun Nuclear Corporation (“SNC” or “Sun Nuclear”) is a provider in radiation oncology quality assurance, delivering patient safety solutions for diagnostic imaging and radiation therapy centers around the world. |  | On December 18, 2020, the Company acquired 100% of the equity interest for approximately $258.1 million of purchase consideration, net of cash acquired.
2021 |  | Dosimetrics |  | Dosimetrics is a provider in the development and production of OSL personal radiation dosimeters and dosimetry solutions, including readers, erasers, software, accessories, and automation systems. |  | On December 1, 2020, the Company acquired 100% of the equity interest for approximately $3.0 million of purchase consideration, net of cash acquired.
2021 |  | Biodex |  | Biodex is a manufacturer and distributor of medical devices and related replacement parts for physical and nuclear medicine, as well as medical imaging applications located in the United States. |  | On September 1, 2020, the Company acquired 100% of the equity interest for approximately $26.9 million of purchase consideration, net of cash acquired.
2020 |  | AWST |  | AWST is a provider of calibration and measurement technologies for radiation medicine applications. |  | On March 31, 2020, the Company acquired 100% of the equity interest for approximately €24.5 million (or $26.9 million) of purchase consideration.
2020 |  | Selmic |  | Selmic is an electronic component manufacturer of sensors, modules, and devices serving in automotive, transportation, medical, security, defense, and telecom industries. |  | On October 31, 2019, the Company acquired 100% of the equity interest for approximately €9.1 million (or $10.2 million) of purchase consideration.
2020 |  | Premium Analyse |  | Premium Analyse is a provider in the radioactive gas detection market and measurement of tritium. |  | On July 19, 2019, the Company acquired 100% of the equity interest for approximately €7.9 million ($8.9 million) of purchase consideration.
2020 |  | Capintec |  | Capintec is a provider of calibration and measurement technologies for nuclear medicine applications. Capintec provides solutions for applications in nuclear medicine, nuclear cardiology, oncology, endocrinology, diagnostic radiology, and radiation therapy. |  | On July 9, 2019, the Company acquired 100% of the equity interest for approximately $14.5 million of purchase consideration.
2019 |  | NRG Dosimetry Services Group |  | NRG Dosimetry Services Group is a provider of dosimetry services in the Netherlands. |  | On October 31, 2018, the Company acquired 100% of the equity interest for approximately €7.8 million (or $9.1 million) of purchase consideration.
Summary of Fair Value of the Assets Acquired and the Liabilities Assumed | The following table presents the preliminary purchase price allocation estimates of the fair value of the assets acquired and liabilities assumed for the material Biodex and SNC acquisitions during the year ended June 30, 2021 (in millions):
|  | Biodex |  |  | SNC |
Date of acquisition |  |  | September 1, 2020 |  |  |  | December 18, 2020 |
Segment |  |  | Medical |  |  |  | Medical |
Goodwill |  | $ | 11.1 |  |  | $ | 130.2 |
Customer relationships (1) |  |  | 2.3 |  |  |  | 59.5 |
Tradenames (2) |  |  | 1.4 |  |  |  | 12.0 |
Non-Compete Agreements (3) |  |  | 0.3 |  |  |  | 7.5 |
Developed Technology (4) |  |  | 2.6 |  |  |  | 46.5 |
Amortizable intangible assets |  | $ | 6.6 |  |  | $ | 125.5 |
Cash |  |  | 4.1 |  |  |  | 18.8 |
Accounts receivable |  |  | 4.0 |  |  |  | 24.0 |
Inventory |  |  | 6.4 |  |  |  | 13.9 |
Property, Plant and Equipment |  |  | 1.0 |  |  |  | 5.9 |
Other current and non-current assets |  |  | 0.6 |  |  |  | 8.0 |
Current liabilities |  |  | (2.6 | ) |  |  | (9.3 | )
Deferred contract revenue |  |  | (0.2 | ) |  |  | (6.5 | )
Other long-term liabilities |  |  | — |  |  |  | (33.6 | )
Net tangible assets acquired |  | $ | 13.3 |  |  | $ | 21.2 |
Purchase consideration (5) |  |  | 31.0 |  |  |  | 276.9 |
Less: cash acquired |  |  | (4.1 | ) |  |  | (18.8 | )
Purchase consideration, net of cash acquired |  | $ | 26.9 |  |  | $ | 258.1 |
Acquiree revenue post acquisition through the period ended June 30, 2021 |  | $ | 32.6 |  |  | $ | 48.9 |
Acquiree income (loss) from operations post acquisition through the period ended June 30, 2021 |  | $ | 0.7 |  |  | $ | (5.5 | )
(1) | The useful life for customer relationships ranges from 10 to 11 years.
(2) | The useful life for tradenames is 7 years.
(3) | The useful life for non-compete agreements ranges from 2 to 3 years.
(4) | The useful life for developed technology ranges from 7 to 10 years.
(5) | Biodex purchase consideration consisted of cash. SNC purchase consideration consisted of $261.9 million cash and $15.0 million of deferred consideration paid in February 2021.
The following summarizes the fair value of assets acquired and liabilities assumed for the acquisitions during the year ended June 30, 2020 (in millions):
|  | Company Name |
|  | Capintec |  |  | Premium Analyse |  |  | Selmic |  |  | AWST |
Date of acquisition |  |  | July 9, 2019 |  |  |  | July 19, 2019 |  |  |  | October 31, 2019 |  |  |  | March 31, 2020 |
Segment |  |  | Medical |  |  |  | Industrial |  |  |  | Industrial |  |  |  | Medical |
Goodwill |  | $ | 6.0 |  |  | $ | 4.3 |  |  | $ | 2.7 |  |  | $ | 4.1 |
Customer relationships (1) |  |  | 2.4 |  |  |  | 2.1 |  |  |  | 2.2 |  |  |  | 20.9 |
Developed technology (2) |  |  | 2.5 |  |  |  | 1.7 |  |  |  | — |  |  |  | — |
Tradename (3) |  |  | 0.1 |  |  |  | 0.1 |  |  |  | 0.2 |  |  |  | — |
Backlog (4) |  |  | 0.3 |  |  |  | — |  |  |  | 0.1 |  |  |  | — |
Amortizable intangible assets |  | $ | 5.3 |  |  | $ | 3.9 |  |  | $ | 2.5 |  |  | $ | 20.9 |
Cash |  |  | 0.6 |  |  |  | 1.2 |  |  |  | 0.4 |  |  |  | — |
Accounts receivable |  |  | 2.0 |  |  |  | 0.5 |  |  |  | 1.0 |  |  |  | — |
Inventory |  |  | 2.7 |  |  |  | 1.4 |  |  |  | 4.2 |  |  |  | 0.6 |
Property and equipment |  |  | 0.8 |  |  |  | 0.2 |  |  |  | 2.1 |  |  |  | 3.8 |
Other assets |  |  | 0.6 |  |  |  | 0.1 |  |  |  | — |  |  |  | 0.3 |
Total tangible assets acquired |  | $ | 6.7 |  |  | $ | 3.4 |  |  | $ | 7.7 |  |  | $ | 4.7 |
Accounts payable |  |  | (1.0 | ) |  |  | (0.2 | ) |  |  | (1.0 | ) |  |  | — |
Accrued expenses and other current liabilities |  |  | (1.1 | ) |  |  | (0.1 | ) |  |  | (0.5 | ) |  |  | (0.4 | )
Pension obligations |  |  | — |  |  |  | (0.1 | ) |  |  | — |  |  |  | — |
Deferred tax liability |  |  | (0.5 | ) |  |  | (1.1 | ) |  |  | (0.7 | ) |  |  | — |
Deferred contract revenue |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (0.6 | )
Financing obligations |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (1.8 | )
Other liabilities |  |  | (0.3 | ) |  |  | — |  |  |  | (0.1 | ) |  |  | — |
Total liabilities assumed |  | $ | (2.9 | ) |  | $ | (1.5 | ) |  | $ | (2.3 | ) |  | $ | (2.8 | )
Net tangible assets acquired |  | $ | 3.8 |  |  | $ | 1.9 |  |  | $ | 5.4 |  |  | $ | 1.9 |
Purchase consideration |  |  | 15.1 |  |  |  | 10.1 |  |  |  | 10.6 |  |  |  | 26.9 |
Less: cash acquired |  |  | (0.6 | ) |  |  | (1.2 | ) |  |  | (0.4 | ) |  |  | — |
Purchase consideration, net of cash acquired |  | $ | 14.5 |  |  | $ | 8.9 |  |  | $ | 10.2 |  |  | $ | 26.9 |
Acquiree revenue post acquisition for twelve months ended June 30, 2020 |  | $ | 15.2 |  |  | $ | 3.0 |  |  | $ | 11.0 |  |  | $ | 2.5 |
Acquiree income (loss) from operations post acquisition for twelve months ended June 30, 2020 |  | $ | 0.7 |  |  | $ | — |  |  | $ | (0.1 | ) |  | $ | (0.4 | )
(1) | The useful life for customer relationships ranges from 7 to 17 years.
(2) | The useful life for developed technology is 7 years.
(3) | The useful life for tradenames is 5 years.
(4) | The useful life for backlog is 1 year.
Summary of Unaudited Pro Forma Financial Information | The unaudited pro forma financial information does not reflect the expected realization of any anticipated cost savings, operating efficiencies, or other synergies that may have been associated with the acquisitions.
(amounts in millions) |  | Year ended June 30, |
|  | 2021 |  |  | 2020 |
Total revenues |  | $ | 670.9 |  |  | $ | 598.7 |
Net loss |  |  | (168.5 | ) |  |  | (151.9 | )
Net loss attributable to Mirion Technologies (TopCo), Ltd stockholders |  |  | (168.4 | ) |  |  | (151.9 | )

X
- Definition Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(2) -URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(3) -URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463 + Details
Name: | us-gaap_BusinessAcquisitionProFormaInformationTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_BusinessCombinationsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463 + Details
Name: | us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472 + Details
Name: | us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration